source
- Triveni Bio raises $65M ahead of upcoming readouts on eczema drugsTriveni Bio announced a $65 million Series C after its second asset for eczema entered clinical studies last month. The Series C was co-led by Ascenta Capital and Janus Henderson Investors and incl…Endpoints · 1mo ago↗ source
- Migraine biotech Vedana Therapeutics makes its debut with $46M Series AVedana Therapeutics has emerged from stealth with $46 million in Series A proceeds with the goal of developing treatments that could free patients from migraines entirely. Available treatments for…Endpoints · 1mo ago↗ source
- A new Westlake-backed biotech takes aim at migrainesVedana Therapeutics emerged from stealth Wednesday with $46 million to support its mission of developing “anti-PACAP” therapies, an increasingly popular strategy for migraine prevention.